Humacyte (NASDAQ:HUMA) Receives “Buy” Rating from BTIG Research

BTIG Research reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report sent to investors on Friday, Marketbeat reports. They currently have a $10.00 target price on the stock.

Several other research analysts have also recently commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. Finally, Benchmark reissued a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $10.00.

Humacyte Stock Up 3.5 %

HUMA stock opened at $5.03 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. Humacyte has a 1-year low of $1.96 and a 1-year high of $9.97. The firm has a fifty day moving average price of $5.78 and a two-hundred day moving average price of $5.89. The firm has a market cap of $598.99 million, a price-to-earnings ratio of -5.03 and a beta of 1.45.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Research analysts predict that Humacyte will post -1.09 EPS for the current year.

Insiders Place Their Bets

In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the transaction, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the business’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 277,090 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the sale, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock worth $6,869,996 over the last 90 days. Corporate insiders own 23.10% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Several institutional investors have recently modified their holdings of HUMA. Vanguard Group Inc. grew its position in shares of Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the period. Millennium Management LLC raised its stake in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after purchasing an additional 450,031 shares in the last quarter. Finally, Private Advisor Group LLC raised its stake in shares of Humacyte by 15.4% during the 2nd quarter. Private Advisor Group LLC now owns 366,600 shares of the company’s stock worth $1,760,000 after purchasing an additional 48,976 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.